The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study

• Published in: Journal of clinical psychopharmacology Vol. 28; no. 2; p. 156
• Main Authors: Marcus, Ronald N, McQuade, Robert D, Carson, William H, Hennicken, Delphine, Fava, Maurizio, Simon, Jeffrey S, Trivedi, Madhukar H, Thase, Michael E, Berman, Robert M
• Format: Journal Article
• Language: English
• Published: United States 01.04.2008
• Subjects: Adult; Akathisia, Drug-Induced - etiology; Antidepressive Agents - adverse effects; Antidepressive Agents - therapeutic use; Aripiprazole; Citalopram - adverse effects; Citalopram - therapeutic use; Cyclohexanols - adverse effects; Cyclohexanols - therapeutic use; Depressive Disorder, Major - drug therapy; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Fatigue - chemically induced; Female; Fluoxetine - adverse effects; Fluoxetine - therapeutic use; Humans; Male; Middle Aged; Paroxetine - adverse effects; Paroxetine - therapeutic use; Piperazines - adverse effects; Piperazines - therapeutic use; Prospective Studies; Psychiatric Status Rating Scales - statistics & numerical data; Quinolones - adverse effects; Quinolones - therapeutic use; Sertraline - adverse effects; Sertraline - therapeutic use; Single-Blind Method; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride; Weight Gain - drug effects; Withholding Treatment - statistics & numerical data

Nonresponse to one or more antidepressants is common and an important public health problem. This study evaluated the efficacy and safety of adjunctive aripiprazole or placebo to standard antidepressant therapy (ADT) in patients with major depressive disorder who showed an inadequate response to at...